What are the safe starting and maximum daily doses of Basaglar (insulin glargine) in units for an adult patient?

Safe Units of Basaglar Insulin

For adults with type 2 diabetes, start Basaglar at 10 units once daily or 0.2 units/kg/day, and for type 1 diabetes, start at approximately one-third of total daily insulin requirements. 1

Starting Doses by Patient Type

Type 2 Diabetes (Insulin-Naïve)

• Standard starting dose: 10 units once daily OR 0.2 units/kg/day 1
• The 2023 ADA guidelines recommend starting basal insulin at 10 units per day OR 0.1-0.2 units/kg per day 2
• Must be administered at the same time each day, though timing can be any time of day 1

Type 1 Diabetes

• Start at approximately one-third of total daily insulin requirements 1
• Must be used concomitantly with short- or rapid-acting mealtime insulin 1
• The remaining two-thirds of daily insulin needs should come from prandial insulin 1

Special Populations Requiring Lower Starting Doses

For hospitalized patients or those at higher risk, use weight-based dosing: 3

• 0.2-0.3 units/kg/day for patients:

  • Age ≥70 years
  • Glomerular filtration rate <60 mL/min

• 0.4 units/kg/day for patients with blood glucose 140-200 mg/dL

• 0.5 units/kg/day for patients with blood glucose 201-400 mg/dL

Maximum Daily Doses and Titration Limits

There is no absolute maximum dose specified in the FDA label, but clinical guidelines provide important upper limits: 1

• Practical upper limit: ~0.5-1.0 units/kg/day 4
• The 2023 ADA guidelines note that basal doses exceeding ~0.5 units/kg/day suggest overbasalization and warrant reassessment 2
• Each Basaglar prefilled pen delivers a maximum of 80 units per injection 1

Critical Caveat: Avoiding Overbasalization

If basal insulin doses approach or exceed 0.5 units/kg/day without achieving glycemic targets, do not continue escalating. Instead, consider: 2, 5

• Adding GLP-1 receptor agonist therapy
• Adding prandial insulin (starting with 4 units at largest meal)
• Evaluating for high bedtime-to-morning glucose differential (≥50 mg/dL)
• Assessing for hypoglycemia or high glucose variability

Titration Protocol

Standard titration approach: 2

1. Set fasting plasma glucose target (typically 80-130 mg/dL)
2. Increase by 2 units every 3 days until reaching fasting glucose target without hypoglycemia
3. If hypoglycemia occurs without clear cause, reduce dose by 10-20%

Alternative titration for some formulations: 4

• Increase by 1 unit per day, OR
• Increase by 2-4 units once or twice per week

Switching from Other Insulins

From NPH insulin (twice daily) to Basaglar (once daily):

• Start at 80% of total daily NPH dose 1

From insulin glargine 300 units/mL to Basaglar:

• Start at 80% of the glargine 300 dose 1

From insulin glargine 100 units/mL to Basaglar:

• Use same dose unit-for-unit 1

Key Safety Considerations

• Never share Basaglar pens between patients, even with needle changes 1
• Rotate injection sites within the same region (abdomen, thigh, or deltoid) to prevent lipodystrophy 1
• Do not inject into areas of lipodystrophy, as this can cause unpredictable absorption and hyperglycemia 1
• Increase blood glucose monitoring frequency during any insulin regimen changes 1
• Do not dilute, mix with other insulins, or administer intravenously 1

Common Pitfalls to Avoid

1. Starting too high in elderly or renally impaired patients - Always use lower weight-based dosing (0.2-0.3 units/kg) 3

2. Continuing to escalate basal insulin indefinitely - Recognize overbasalization signals and add complementary therapies instead 2, 5

3. Forgetting to reduce dose when switching from NPH or glargine 300 - This increases hypoglycemia risk significantly 1

4. Using sliding scale insulin alone - This approach results in worse glycemic control and 3-fold increased hyperglycemia risk compared to scheduled basal-bolus regimens 3